Document is current
Any future updates will be listed below
-
Authors
Paul, Barry
Rodriguez, Cesar
Usmani, Saad Z.
- License Information
-
More Information
Article History
Accepted: 3 March 2022
First Online: 12 April 2022
Declarations
:
: No external funding was used in the preparation of this article.
: BP reports personal fees from AbbVie, personal fees from Amgen, stock ownership from BMS, personal fees from Genentech, personal fees from Janssen, and personal fees from Regeneron, outside the submitted work. CR reports personal fees from Amgen, personal fees from BMS, personal fees from Janssen, personal fees from Karyopharm, personal fees from Oncopeptides, and personal fees from Janssen, outside the submitted work. SZU reports research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda and personal fees (consulting) from AbbVie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, and TeneoBio.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed equally to the design, authorship, and revision of the manuscript.
